Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Yau, Thomas; Galle, Peter R; Decaens, Thomas; Sangro, Bruno; Qin, Shukui; da Fonseca, Leonardo G; Karachiwala, Hatim; Blanc, Jean-Frederic; Park, Joong-Won; Gane, Edward; Pinter, Matthias; Peña, Ana Matilla; Ikeda, Masafumi; Tai, David; Santoro, Armando; Pizarro, Gonzalo; Chiu, Chang-Fang; Schenker, Michael; He, Aiwu; Chon, Hong Jae; Wojcik-Tomaszewska, Joanna; Verset, Gontran; Wang, Qi Qi; Stromko, Caitlyn; Neely, Jaclyn; Singh, Prianka; Jimenez Exposito, Maria Jesus; Kudo, Masatoshi

doi:10.1016/s0140-6736(25)00403-9

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

BACKGROUND Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresec…